Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

Alteogen Inc.

www.alteogen.com

Latest From Alteogen Inc.

Bookmark
  • News

Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers

By Ian Haydock, Jung Won Shin and Joseph Haas

Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.

Deals Business Strategies
Bookmark
  • Analysis

Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India

By Anju Ghangurde

Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.

Biosimilars Strategy
Bookmark
  • Analysis

Mylan Eylea Biosimilar Gets Green Signal For Trials In India

By Anju Ghangurde

Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.

Research & Development Clinical Trials
Bookmark
  • News

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

By Joseph Haas, John Davis, Alex Shimmings, Jung Won Shin and Ian Haydock

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Alteogen Inc.
  • Senior Management
  • Soon Jae Park, PhD, CEO
    Moon Hwan Park, SVP, CFO
    Hye-Shin Chung, PhD, CTO
    Kyeong-Hoon Jeong, PhD, VP, Head R&D
  • Contact Info
  • Alteogen Inc.
    Phone: 423848780
    62 Yuseong-daero 1628, beon-gi
    Yuseong-gu
    Daejeon, 34054
    South Korea
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By